William Rastetter has become non-executive chairman of Illumina’s board of directors, while current board chair John Stuelpnagel has been appointed to the new position of chief operating officer, Illumina announced last week. Rastetter will continue to serve as full-time executive chairman of Biogen Idec. He was the CEO of Biogen from 1986 to 2003, when it merged with Idec Pharamaceuticals. Stuelpnagel is a founding member of Illumina, and once served as its CEO and chief financial officer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.